Roferon-A in combination with Tigason in cutaneous T-cell lymphomas.
In cutaneous T-cell lymphomas (CTCL; mycosis fungoides and Sézary syndrome), the standard therapies tend to be effective but not curative. Single drug therapy with either interferon-alpha or retinoids shows a response rate of about 45%. In this article, we report the results obtained in the treatment of CTCL with a combined therapy. To date, four clinical studies have been carried out using a combination of low doses of interferon-alpha and retinoids for treatment in the early stages of CTCL. The mechanism of action of this combination therapy is unknown.
Dreno
B
B
Department of Dermatology, Hôtel Dieu, Nantes, France.
Celerier
P
P
Litoux
P
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005050:Etretinate / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D011994:Recombinant Proteins; D012176:Retinoids / Q000008:administration & dosage / Q000627:therapeutic use
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012176:Retinoids; D005050:Etretinate